PRAX, US74006W2070

PRAX stock: UBS starts coverage of Praxis Precision Medicines stock at USD 706.00

Published on 10/23/2026 at 02:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Praxis reported second-quarter expenses of USD 96.90 million. Praxis Precision Medicines stock held USD 1.40 billion in cash on June 30, 2026.

Pipeline dates shape valuation

UBS set a USD 706.00 target for Praxis Precision Medicines on October 15, 2026.
Second-quarter operating expenses reached USD 96.90 million in the quarter ended June 30, 2026.
Praxis Precision Medicines stock was last at USD 258.92 on Nasdaq on October 22, 2026 at 4:00 p.m. EDT.

PRAX, US74006W2070, Illustration mit AI erstellt.

Praxis Precision Medicines (ISIN US74006W2070) received a USD 706.00 price target from UBS on October 15, 2026, when the bank initiated coverage with a Buy rating, as Markets Insider reported. The setup now turns on regulatory dates and the companys spending needed for a potential commercial launch.

Analyst targets reset the frame

UBS cited ulixacaltamide for essential tremor and relutrigine for developmental and epileptic encephalopathies as key catalysts. The same report identified a January 29, 2027 PDUFA decision for ulixacaltamide and described Praxis as a clinical-stage biotechnology company.

JPMorgan initiated coverage on October 16, 2026, with an Overweight rating and a USD 700.00 target, according to MarketScreener. That clustering of targets leaves clinical execution, rather than current product revenue, as the central valuation variable.

Three October steps matter

On October 2, 2026, Praxis disclosed inducement grants covering 3,478 shares for fourteen new employees, according to GlobeNewswire. On October 6, 2026, BTIG raised its target from USD 810.00 to USD 826.00. On October 15, 2026, UBS initiated coverage at USD 706.00.

What comes next for the pipeline?

The next two dated catalysts are the December 27, 2026 PDUFA target for relutrigine and the January 29, 2027 PDUFA decision for ulixacaltamide, according to the earnings-call discussion carried by Benzinga. The companys second-quarter operating expenses were USD 96.90 million, including USD 69.40 million for research and development and USD 27.50 million for general and administrative costs.

Cash supports the launch build

Praxis used USD 77.54 million in operating cash during the quarter ended June 30, 2026. Cash, cash equivalents and marketable securities totaled USD 1.40 billion at the quarter end, supporting managements stated runway into 2028.

Stock stays tied to approvals

PRAX was last at USD 258.92 on Nasdaq on October 22, 2026 at 4:00 p.m. EDT. The quote put market capitalization at USD 7.2 billion, while the 52-week range stood at USD 154.45 to USD 392.70.